Background: Molnupiravir is an oral prodrug with antiviral activity against severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2). Molnupiravir was initially developed for …

Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …

Background: Nirmatrelvir/ritonavir (NMV/r) is an oral antiviral drug used to treat mild-to-
moderate coronavirus disease 2019 (COVID-19) in patients aged 12 years or older at high …

Background Nirmatrelvir-ritonavir is recommended for persons at risk for severe coronavirus
disease 2019 (COVID-19) but remains underutilized. Information on which eligible groups …

Background There is an urgent need for therapeutic strategies for inpatients with severe or
critical COVID-19. The evaluation of the clinical benefits of nirmatrelvir and ritonavir (Nmr/r) …

Background Studies have established the short-term efficacy of nirmatrelvir–ritonavir in
managing COVID-19, yet its effect on post-COVID-19 condition, especially in patients …

Real-life experience of molnupiravir treatment is lacking, especially in people hospitalized
for underlying diseases not related to COVID-19. We conducted a retrospective analysis …

Objective To compare the effectiveness of Paxlovid vs. sotrovimab and molnupiravir in
preventing severe COVID-19 outcomes in non-hospitalised high-risk COVID-19 adult …

Background: The use of outpatient antiviral treatment for high-risk patients with coronavirus
disease 19 (COVID-19) is crucial in preventing progression to severe COVID-19 and …

Purpose Molnupiravir is an oral antiviral agent authorized for emergency use to treat mild to
moderate cases of coronavirus disease 2019 (COVID-19) in adults at high risk for …